Viral Breakthrough Is Associated With Resistance Using Direct Acting Agents in Patients Treated for Chronic Hepatitis C Infection

2014 ◽  
Vol 48 (6) ◽  
pp. 548-552
Author(s):  
Kali Zhou ◽  
Jessica Ferguson ◽  
Sherona Bau ◽  
Sammy Saab
2012 ◽  
Vol 8 (1) ◽  
pp. e1002339 ◽  
Author(s):  
Bambang S. Adiwijaya ◽  
Tara L. Kieffer ◽  
Joshua Henshaw ◽  
Karen Eisenhauer ◽  
Holly Kimko ◽  
...  

2017 ◽  
Vol 10 (2) ◽  
pp. 277-282 ◽  
Author(s):  
Ara A. Kardashian ◽  
Paul J. Pockros

Advances in the treatment of chronic hepatitis C has been one of the pinnacles of medical science in the last 25 years. The age of direct-acting antivirals (DAAs) has led to cure rates >95% with shorter duration and low toxicity regimens, thus changing the landscape of the era of pegylated interferon and ribavirin (RBV). However, there remain some challenges with these therapies as there are multiple regimens available with a fair amount of sophistication required to administer them. Treatment continues to require knowledge of prior treatment status, viral genotype and fibrosis assessment, thus affording an opportunity for improvement in future regimens. This update reviews some upcoming therapies for the treatment of chronic hepatitis C.


Sign in / Sign up

Export Citation Format

Share Document